Last reviewed · How we verify
AGN-199201 Dose A
AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues.
AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues. Used for Muscle wasting or sarcopenia (phase 2 development).
At a glance
| Generic name | AGN-199201 Dose A |
|---|---|
| Sponsor | Allergan |
| Drug class | Selective androgen receptor modulator (SARM) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Musculoskeletal / Endocrinology |
| Phase | Phase 2 |
Mechanism of action
As a SARM, AGN-199201 binds to and activates the androgen receptor with tissue-selective activity, potentially providing anabolic effects in muscle and bone while minimizing androgenic side effects in other tissues. This selective activation profile is designed to improve muscle function and physical performance in conditions where androgen signaling is beneficial.
Approved indications
- Muscle wasting or sarcopenia (phase 2 development)
Common side effects
- Testosterone suppression
- Liver enzyme elevation
- Acne
Key clinical trials
- A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia (PHASE2)
- A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
- AGN-199201 for the Treatment of Erythema With Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-199201 Dose A CI brief — competitive landscape report
- AGN-199201 Dose A updates RSS · CI watch RSS
- Allergan portfolio CI